InMed Pharmaceuticals Cannabinoid-Based Treatment To Severe Diseases
InMed specializes in developing cannabinoid-based pharmaceuticals to treat severe diseases. Proprietary technologies under development will enable InMed to produce cannabinoids without growing plants, and match drug combinations to specific diseases.
InMed Pharmaceuticals is a pre-clinical stage biopharmaceutical company. It specializes in developing novel therapies through research and development into the extensive pharmacology of cannabinoids. It is coupled with innovative drug delivery systems.
InMed is utilizing its proprietary bioinformatics assessment tool to identify bioactive compounds. Within the cannabis plant, they have the potential to have physiological impacts on specific diseases. The goal is to identify new drug candidates that optimize therapeutic benefit while limiting adverse effects.
InMed’s proprietary is in silico drug/disease bioinformatics assessment tool. Cannabinoid biosynthesis Technology and Drug Development Pipeline are the fundamental value drivers of the Company.
For more information on InMed Pharmaceuticals (IN:TSX) please fill out the form below.